BR9815496A - Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório - Google Patents

Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório

Info

Publication number
BR9815496A
BR9815496A BR9815496-6A BR9815496A BR9815496A BR 9815496 A BR9815496 A BR 9815496A BR 9815496 A BR9815496 A BR 9815496A BR 9815496 A BR9815496 A BR 9815496A
Authority
BR
Brazil
Prior art keywords
protein
vectors
code
nucleic acid
respiratory syncytial
Prior art date
Application number
BR9815496-6A
Other languages
English (en)
Inventor
Xiaomao Li
Michel H Klein
Suryaprakesh Sabhara
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of BR9815496A publication Critical patent/BR9815496A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"VACINAS DE áCIDO NUCLéICO QUE CODIFICAM PROTEìNAG DE VìRUS SINCICIAL RESPIRATóRIO". São descritos vetoresnão replicantes, como vetores de plasmídeo, que contêm umaseq³ência de nucleotídeo codificando para uma proteina G devírus sincicial respiratório (RSV) e um promotor para tal seq³ência,preferivelmente um promotor de citomegalovírus. Tais vetorestambém podem conter uma seq³ência de nucleotídeo adicionallocalizada adjacente à seq³ência de codificação de proteína GRSV para aumentar a capacidade de imunoproteção da proteínaG RSV quando expressa in vivo. Tais vetores não-replicantespodem ser utilizados para imunizar um hospedeiro, incluindo umhospedeiro humano, contra infecção por RSV por administração aomesmo. Tais vetores não-replicantes também podem ser utilizadospara produzir anticorpos para detecção de infecção por RSV emuma amostra.
BR9815496-6A 1997-07-18 1998-07-16 Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório BR9815496A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89644297A 1997-07-18 1997-07-18
PCT/CA1998/000697 WO1999004010A1 (en) 1997-07-18 1998-07-16 Nucleic acid vaccines encoding g protein of respiratory syncytial virus

Publications (1)

Publication Number Publication Date
BR9815496A true BR9815496A (pt) 2001-12-18

Family

ID=25406219

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815496-6A BR9815496A (pt) 1997-07-18 1998-07-16 Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório

Country Status (8)

Country Link
EP (1) EP0996730A1 (pt)
JP (1) JP2001512662A (pt)
CN (1) CN1174099C (pt)
AU (1) AU756222B2 (pt)
BR (1) BR9815496A (pt)
CA (1) CA2296089A1 (pt)
NZ (1) NZ502626A (pt)
WO (1) WO1999004010A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083925A (en) * 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
FR2790959B1 (fr) * 1999-03-15 2003-06-27 Pf Medicament Utilisation de fractions membranaires bacteriennes a effet adjuvant, leurs procedes de preparation et composition pharmaceutique les contenant
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
AU5442501A (en) * 1999-12-01 2001-07-09 Chiron Corporation Eliciting HCV-specific antibodies
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
KR100938105B1 (ko) * 2007-09-21 2010-01-21 이화여자대학교 산학협력단 호흡기 신시치아 바이러스 백신
NZ619953A (en) 2008-07-16 2015-06-26 Inst Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
WO2012053856A2 (ko) 2010-10-21 2012-04-26 이화여자대학교 산학협력단 호흡기 신시치아 바이러스 백신 조성물 및 그의 제조방법
CN111303278B (zh) * 2013-04-15 2022-09-06 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
EP4013782A4 (en) * 2019-08-12 2023-12-27 Advaccine (Suzhou) Biopharmaceuticals Co. Ltd. IMMUNE COMPOSITION COMPRISING A RESPIRATORY SYNZYTIAL VIRUS (RSV) G POLYPEPTIDE
WO2024139647A1 (zh) * 2022-12-26 2024-07-04 中国医学科学院基础医学研究所 一种人乳头瘤病毒16型dna疫苗及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections

Also Published As

Publication number Publication date
NZ502626A (en) 2002-09-27
WO1999004010A1 (en) 1999-01-28
AU8427898A (en) 1999-02-10
EP0996730A1 (en) 2000-05-03
AU756222B2 (en) 2003-01-09
JP2001512662A (ja) 2001-08-28
CA2296089A1 (en) 1999-01-28
CN1174099C (zh) 2004-11-03
CN1271389A (zh) 2000-10-25

Similar Documents

Publication Publication Date Title
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
AU1026692A (en) Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
RU95115239A (ru) Аналог эритропоэтина
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
MXPA01008966A (es) Vacunas contra el virus sincicial respiratorio a base de acido nucleico.
ES2070866T3 (es) Vacunas recombinantes contra la coccidiosis.
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
ATE380037T1 (de) Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
BR9814276A (pt) Antìgenos de superfìcie
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
ATE312920T1 (de) Dna immunisierung gegen chlamydia infektion
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
EP0658623A3 (en) Attenuated herpes viruses, herpes viruses that contain foreign DNA encoding an amino acid sequence, and vaccines containing them.
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
BR9803960A (pt) Gene de desidrogenase de d-sorbitol.
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
DK0892054T3 (da) Clostridium perfringens-vaccine
MXPA02005506A (es) Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
WO1998011234A3 (en) Human protein kinases
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
IE890087L (en) Recombinant human interleukin-1 alpha polypeptides
EP1731611A3 (en) Eimeria hydrophilic polypeptides as vaccines

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART 36 DA LPI (LEI 9.279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.